About: Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections
Creator	Asha, Kumari Khanna, Madhu Kumar, Binod Kumar, Prashant Sanicas, Melvin Meseko, Clement
Source	Medline; PMC
abstract	Several viruses cause pulmonary infections due to their shared tropism with cells of the respiratory tract. These respiratory problems due to viral infection become a public health concern due to rapid transmission through air/aerosols or via direct-indirect contact with infected persons. In addition, the cross-species transmission causes alterations to viral genetic makeup thereby increasing the risk of emergence of pathogens with new and more potent infectivity. With the introduction of effective nucleic acid-based technologies, post translational gene silencing (PTGS) is being increasingly used to silence viral gene targets and has shown promising approach towards management of many viral infections. Since several host factors are also utilized by these viruses during various stages of infection, silencing these host factors can also serve as promising therapeutic tool. Several nucleic acid-based technologies such as short interfering RNAs (siRNA), antisense oligonucleotides, aptamers, deoxyribozymes (DNAzymes), and ribozymes have been studied and used against management of respiratory viruses. These therapeutic nucleic acids can be efficiently delivered through the airways. Studies have also shown efficacy of gene therapy in clinical trials against respiratory syncytial virus (RSV) as well as models of respiratory diseases including severe acute respiratory syndrome (SARS), measles and influenza. In this review, we have summarized some of the recent advancements made in the area of nucleic acid based therapeutics and highlighted the emerging roles of nucleic acids in the management of some of the severe respiratory viral infections. We have also focused on the methods of their delivery and associated challenges.
has issue date	2018-12-20(xsd:dateTime)
bibo:doi	10.3390/jcm8010006
bibo:pmid	30577479
has license	cc-by
sha1sum (hex)	e67eb3bd9090630fa37b601957ed1dcc088901cf
schema:url	https://doi.org/10.3390/jcm8010006
resource representing a document's title	Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections
has PubMed Central identifier	PMC6351902
has PubMed identifier	30577479
schema:publication	J Clin Med
resource representing a document's body	covid:e67eb3bd9090630fa37b601957ed1dcc088901cf#body_text
is schema:about of	named entity 'infections' named entity 'targets' named entity 'infectivity' named entity 'pathogens' covid:arg/e67eb3bd9090630fa37b601957ed1dcc088901cf named entity 'clinical trials' named entity 'studied' named entity 'therapeutic' named entity 'health concern' named entity 'problems' named entity 'therapeutic' named entity 'factors' named entity 'nucleic acid' named entity 'respiratory infections' named entity 'biosensor' named entity 'RNA viruses' named entity 'respiratory syncytial virus' named entity 'antibodies' named entity 'respiratory infections' named entity 'antigens' named entity 'highly conserved' named entity 'transposons' named entity 'influenza virus' named entity 'viral diseases' named entity 'RNA molecules' named entity 'aptamers' named entity 'MDCK' named entity 'H3, H5' named entity 'guanosine' named entity 'influenza virus' named entity 'molecule' named entity 'RSV' named entity 'gene' named entity 'hybridizing' named entity 'gene' named entity 'transcriptional silencing' named entity 'ORF' named entity 'RNA' named entity 'influenza virus' named entity 'avian influenza virus' named entity 'specific sites' named entity 'therapeutic agents' named entity 'infection' named entity 'polymerase' named entity 'Aptamers' named entity 'binding protein' named entity 'significant results' named entity 'ASOs' named entity 'RSV' named entity 'cell line' named entity 'influenza' named entity 'hydrolytic cleavage' named entity 'RNA molecule' named entity 'follow-up' named entity 'nucleic acid' named entity 'mRNA' named entity 'protein' named entity 'vaccine' named entity 'siRNAs' named entity 'H3N2' named entity 'H5N1' named entity 'public health' named entity '1.2' named entity 'CPP' named entity 'nucleic acids' named entity 'genetic information' named entity 'therapeutic agent' named entity 'mRNA' named entity 'Adenoviruses' named entity 'ribozymes' named entity 'lungs' named entity 'prophylactic' named entity 'RNA viruses' named entity 'virus replication' named entity 'respiratory viral infections' named entity 'SPR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software